Interferon-alpha Treatment of Chronic Cough in Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis

• Status: Terminated
• Trial end date: 2012-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether lozenges containing interferon-alpha can reduce the frequency and severity of coughing in patients with chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Amarillo Biosciences, Inc.
• Collaborator: Texas Tech University Health Sciences Center
• Treatments: Interferon alpha-2; Interferon-alfa-1b; Interferon-alpha; Interferons

Criteria

Inclusion Criteria:

For all patients

• history of clinically significant chronic cough for > 3 months

• For COPD patients

• >40 years of age

• 20-pack-year history of smoking

• GOLD classification of Stage 1 or higher

• For IPF patients

• > 50 years of age

• history of unexplained dyspnea on exertion of > 3 months

• exhibits coughing and bilateral, basilar, inspiratory crackles on physical exam

• presents as being in a stable phase of IPF

• lung biopsy or HRCT indicative of IPF

Exclusion Criteria:

• ACE inhibitor use

• GERD

• current cancer or history of lung cancer

• non-ambulatory

• hospitalized in the previous 12 months for heart failure